In response to inflammatory mediators such as interferon (IFN)-γ, which is the primary mediator of T cell-mediated anti-tumor immunity, cancer cells initiate an adaptive (secondary) resistance program to survive anti-tumor immune responses [24, 25]. This evidence concerns the gene IFNG and neoplasm.